A human pan-genomic analysis reconfigures the genetic

and epigenetic make up of facioscapulohumeral ³ muscular dystrophy

- 4
- Authors: Valentina Salsi, ¹[†] Matteo Chiara,^{2,3}[†] Sara Pini,¹ Paweł Kuś,⁴ Lucia Ruggiero,⁵ 5 Silvia Bonanno,⁶ Carmelo Rodolico,⁷ Stefano C. Previtali,⁸ Maria Grazia D'Angelo,⁹ Lorenzo 6 Maggi,⁶ Diego Lopergolo,^{10,11} Marek Kimmel,^{4,12} Filippo M. Santorelli,¹³ Graziano Pesole,^{3,14} 7 Rossella G. Tupler^{1,15,16*1} 8 9 Authors' Affiliations: 10 1. Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, 41125, Italy. valentina.salsi@unimore.it; pini.saraps@gmail.com; 11 rossella.tupler@unimore.it*. 12 2. Dipartimento di Bioscienze, Università degli Studi di Milano, Milan, 20133, Italy. 13 14 matteo.chiara@unimi.it. 15 3. Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies, Consiglio 16 Nazionale delle Ricerche. Bari. 70126. Italy. matteo.chiara@unimi.it; 17 graziano.pesole@uniba.it. 18 4. Department of Systems Biology and Engineering, Silesian University of Technology, Gliwice, 44-100, Poland. pawel.s.kus@protonmail.com; kimmel@rice.edu. 19 20 5. Department of Neurosciences, Reproductive and Odontostomatological Sciences, University Federico II of Naples, Naples, 80131, Italy. ruggilucia@gmail.com. 21 22 6. IRCCS Foundation, C. Besta Neurological Institute, Milan. 20133. Italv. Silvia.Bonanno@istituto-besta.it; Lorenzo.Maggi@istituto-besta.it. 23 24
- Department of Clinical and Experimental Medicine, University of Messina, Messina, NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
- 25 98125 Italy. carmelo.rodolico@unime.it.

- 26 8. INSPE and Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan,
- 27 20133, Italy. previtali.stefano@hsr.it.
- 28 9. Department of Neurorehabilitation, IRCCS Eugenio Medea, Bosisio Parini, 23842, Italy.
- 29 grazia.dangelo@lanostrafamiglia.it.
- 30 10. Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, 53100
- 31 Italy. diego.lopergolo@unifi.it.
- 32 11. UOC Neurologia e Malattie Neurometaboliche, Azienda Ospedaliero Universitaria
- 33 Senese, Policlinico Le Scotte, 53100 Siena, Italy. <u>diego.lopergolo@unifi.it.</u>
- 12. Departments of Statistics and Bioengineering, Rice University, Houston, TX, 77005,
- 35 United States. kimmel@rice.edu.
- 36 13. IRCCS Fondazione Stella Maris, Pisa, 56128, Italy. filippo3364@gmail.com.
- 14. Department of Biosciences, Biotechnology and Environment, University of Bari "A.
- 38 Moro", Bari, 70126, Italy. graziano.pesole@uniba.it.
- 39 15. Department of Molecular, Cell, and Cancer Biology, University of Massachusetts
- 40 Medical School, Worcester, MA 01605, United States. rossella.tupler@unimore.it*.
- 41 16. Li Weibo Institute for Rare Diseases Research at the University of Massachusetts
- 42 Medical School, Worcester, MA 01605, United States. rossella.tupler@unimore.it*.

43

- 44 † Valentina Salsi and Matteo Chiara contributed equally to this study and reserve the right to list themselves
 45 as first author.
- 46

47 ***Corresponding Author:**

Rossella Tupler, M.D., Ph.D., Department of Biomedical, Metabolic and Neural Sciences, University of
Modena and Reggio Emilia, Email: <u>rossella.tupler@unimore.it</u>).

51 **ABSTRACT**

52 Facioscapulohumeral muscular dystrophy (FSHD) is the only human disease associated 53 with epigenetic changes at a macrosatellite array. Almost 95% of FSHD cases carry a 54 reduced number (\leq 10) of tandem 3.3 kilobase repeats, termed D4Z4, on chromosome 4q35; 55 remaining cases bear variants in chromatin remodeling factors, such as SMCHD1, 56 DNMT3B, LRIF1. Reduced CpG methylation is used for the molecular diagnosis of FSHD, 57 but D4Z4-like sequences dispersed in the genome can generate ambiguous results. By 58 analyzing complete haplotype level assemblies from the T2T-CHM13 human genome and 59 86 haploid genomes from the human pangenome project, we uncovered the extensive 60 number of D4Z4-like elements and their widespread inter- and intra-individual variability. An 61 original analytical approach was developed to elucidate this previously unaccounted wealth 62 of D4Z4-like elements and to analyze CpG methylation at D4Z4 in bisulfite-treated DNA 63 from 29 FSHD index cases and 15 relatives. Integrated analysis of clinical phenotype, D4Z4 64 CpG methylation level and gene variants showed that low D4Z4 methylation was associated with variants in the SMCHD1 gene, but not with the patients' clinical phenotypes. This is the 65 66 first study showing the relevance of the pangenome and T2T-CHM13 assemblies for investigating the genotype-phenotype correlation in genetic diseases. The extension and 67 68 the variability of D4Z4-like elements scattered throughout the human genome and the 69 inconsistent association of phenotypes with methylation profiles advocate for a critical 70 revision of FSHD diagnostic tests based on D4Z4 CpG methylation assays and indicate that molecular investigations must be complemented by family studies for the proper 71 72 interpretation of results.

73

74 Introduction

75

76 Facioscapulohumeral muscular dystrophy (FSHD) is the third most common form of hereditary myopathy with an estimated prevalence from 1/8,000 to 1/20,000^{1,2}. FSHD is the 77 78 only hereditary human disease associated with reductions in copy number of a 3.3 kb 79 macrosatellite³, termed D4Z4. In the general population, the size of the D4Z4 repeat varies 80 between 11 and 150 units, whereas FSHD patients carry fewer than 11 repeats⁴. Each copy of the 3.3 kb D4Z4 repeat contains an open reading frame (ORF) with two homeobox 81 82 domains, named DUX4-Like (DUXL)⁵, and two different classes of GC-rich repetitive DNA^{6,7}: hhspm3, a member of a low copy human repeat family⁸, and LSau, a middle 83 84 repetitive DNA family^{8,9}. A tandemly arrayed D4Z4 repeat with 98% identity to the 4q35 array is located at 10g26¹⁰, but only alleles with reduced D4Z4 copy number on 85 86 chromosome 4g35 have been associated with FSHD (Figure 1).

87 Two genetically distinct FSHD subtypes, FSHD1 and FSHD2, are currently described. In FSHD1 [OMIM #158900], the reduction of 4g35-D4Z4 repeats below a critical 88 threshold (10 or fewer repeat units, RU)¹¹ is thought to determine epigenetic alterations and 89 the inappropriate expression of nearby genes leading to disease ¹²⁻¹⁴. In FSHD2 [OMIM 90 #158901] affected individuals carry two D4Z4 arrays in the healthy range (>10 RU), but bear 91 92 damaging heterozygous variants in chromatin remodeling factor genes, such as SMCHD1 93 (for structural maintenance of chromosomes flexible hinge domain containing 1)¹⁵, DNMT3B (for methyltransferase 3B)¹⁶ and *LRIF1* (for ligand-dependent nuclear receptor interacting 94 factor 1)¹⁷. It has thus been proposed that similar to the reduction of D4Z4 RU, the 95 96 inactivation of these genes alters the epigenetic configuration of the D4Z4 array at 4g35 97 (Figure 1). Recent studies linked the molecular etiology of FSHD with the inappropriate 98 expression of the DUX4 protein from the terminal D4Z4 repeat. Only a specific haplotype 99 labelled 4qA-PAS is considered to be permissive for DUX4 protein expression, due to the

100 presence of a 260-bp sequence, termed pLAM, which provides a 3'-terminal exon (Exon 3) 101 and a polyadenylation signal (PAS) (AUUAAA) in juxtaposition to the terminal copy of DUX4 ORF (hereafter ter-DUX4) on 4q^{18,19} (Figure S1). Although a similar arrangement is 102 103 observed also on chr 10q26, at this locus the PAS signal is disrupted by a single nucleotide 104 variant (AUCAAA), preventing the polyadenylation of the ter-DUX4 mRNA. By analogy, 4gB, 105 an alternative (to 4qA-PAS) haplotype at 4q (Figure S1), is considered not permissive for 106 the expression of the DUX4 protein due to the lack of pLam. Based on these observations 107 (D4Z4 reduced copy number or heterozygous variants in chromatin remodelers, associated 108 with 4qA-PAS haplotype) a reduction of CpG methylation of D4Z4 has been proposed as a 109 faithful indicator of anomalous DUX4 gene expression and it is used as a proxy of disease 110 status in the clinical setting²⁰.

111 This model is in contrast with clinical and epidemiological data showing reduced penetrance and clinical variability in FSHD families²¹⁻²⁷, as well as with observations 112 113 obtained by adopting an articulate neurological assessment for the study of genotype-114 phenotype correlation in FSHD. This latter approach includes the phenotypic classification 115 of probands and relatives by applying the Comprehensive Clinical Evaluation Form 116 (CCEF)²⁸, which beside quantifying the degree of motor disability²⁹, classifies individuals on 117 the basis of detailed phenotypic features which include parameters such as age at onset or 118 site of disease onset beside the detailed description of muscle impairment. Four main 119 descriptive categories have been created. They identify: (1) subjects presenting facial and 120 scapular girdle muscle weakness typical of FSHD (category A, subcategories A1-A3), (2) 121 subjects presenting an incomplete phenotype with muscle weakness limited to scapular 122 girdle or facial muscles (category B, subcategories B1 and B2), (3) asymptomatic or healthy 123 subjects (category C, subcategories C1 and C2), and (4) subjects with myopathic 124 phenotypes presenting clinical features not consistent with FSHD canonical phenotype 125 (category D, subcategories D1 and D2)²⁸. The application of this methodology for the

126 stratification of clinical phenotypes has permitted the quantification of the large phenotypic 127 variability observed in individuals carrying a D4Z4 Reduced Allele (DRA) which is in contrast 128 to the indication that a positive molecular test is the only determining aspect for FSHD 129 diagnosis^{30–37}. Studies also showed that the different categories are associated with 130 different disease trajectories; in particular subjects assessed with a classical FSHD 131 phenotype (Category A) display a steeper functional decline, than subjects with limited muscle impairment (Category B) ^{31,35}. Large genotype-phenotype studies also highlighted 132 differences between probands and relatives, including 30-50% of relatives remaining non-133 134 penetrant carriers. Consistent with these findings it has been assessed that DRA with 4-8 RU have the frequency of a common polymorphism (3% in the general population^{25,38–40}), 135 136 which is not compatible with the incidence of FSHD; moreover the DRA 4qA-PAS haplotype 137 has a 2% frequency in the human population³⁹. Finally, studies reported a wide variability in 138 D4Z4 CpG methylation levels among FSHD index cases and FSHD families with no clear 139 association between D4Z4 methylation status and disease manifestations or severity^{32,41}.

140 Here, we report the results of comparative analyses of 86 haplotype-level assemblies from the Human Pangenome Project dataset (hereafter PGR)⁴² and the outcome of high-141 142 throughput CpG methylation assay of the D4Z4 repeat based on the T2T-CHM13 human 143 genome assembly (hereafter T2T). Our study displays all the potential of complete, high-144 quality haplotype level genome assemblies for the analysis of D4Z4 arrays in human 145 diseases, confirms the high frequency of the permissive 4qA-PAS haplotype, which is 146 comparable to a common polymorphism and shows that across the 3.3 kb D4Z4 elements 147 only two sequences are 4q/10q-specific and amenable for the study of methylation patterns 148 in FSHD. This refined CpG methylation assay reveals that 4q/10q-specific reduced 149 methylation correlates with the presence of damaging SMCHD1 heterozygous variants, but not with the clinical status of FSHD2 cases and advocate revisions of previous findings 150 151 based on the GRCh38 reference (hereafter hg38).

152

153 Subjects and methods

154

155 **Participants**

The study cohort included 26 subjects (8F, 18M) reported to the Miogen Laboratory of the 156 University of Modena and Reggio Emilia for the diagnosis of FSHD⁴³. These cases carried 157 158 D4Z4 alleles with 10 or more repeats. In 8 cases the study was extended to one or both 159 parents, for a total of 14 subjects (7F, 7M). Overall, 5 trios and 3 parent-child couples were 160 analyzed. Four subjects carrying a 4U DRA were also included (2F, 2M). In three of these 161 subjects (Family C individuals III-1 and III-3; Family 1252 subject 297/08³²) D4Z4 162 methylation was previously assessed through the BSS assay using primer sets specific for 163 the distal 4qA and 4qA-Long (4qA-L) D4Z4 repeat regions³².

The clinical phenotype was determined (Table S1) according to the Comprehensive 164 165 Clinical Evaluation Form (CCEF), which evaluates the distribution and degree of motor 166 impairment, age at onset of motor impairment and site of muscle weakness at onset, the 167 presence of typical and atypical symptoms²⁴. The CCEF has been developed by the Italian 168 Clinical Network for FSHD to classify subjects on the basis of these clinical features. The 169 CCEF classifies: 1) subjects presenting facial and scapular girdle muscle weakness typical 170 of FSHD (category A, subcategories A1-A3), 2) subjects with muscle weakness limited to 171 muscles (category subcategories scapular girdle or facial В B1, B2), 3) 172 asymptomatic/healthy subjects (category C, subcategories C1, C2), 4) subjects with myopathic phenotype presenting clinical features not consistent with FSHD canonical 173 174 phenotype (category D, subcategories D1, D2). Degree of motor impairment was also established by applying a standardized evaluation that generates the FSHD score ²⁹. 175

Signed informed consent was obtained from all the subjects prior to the inclusion inthe study.

178

179 **Bisulfite sequencing**

180 Bisulfite sequence analysis was performed on high molecular weight genomic DNA 181 obtained from peripheral frozen blood through phenol-chloroform extraction. To assess the methylation level at D4Z4 locus, specific primer sets were designed on hg38 genome 182 assembly using MethPrimer tool⁴⁴. No CpG sites were allowed in the primer sequence. The 183 184 amplicon selection was based on following criteria: i) the sequences contain SNPs allowing 185 to discriminate between the 4g and 10g D4Z4 repeats; and ii) include the maximum number 186 of CpG sites possible. Amplicons were representative of the whole D4Z4 array and included 187 functional domains such as the D4Z4 binding element (DBE)¹². Table S2 and Table S3, Figure S2 summarize the characteristics of the four selected primer sets. Specific Illumina 188 189 adapters were added to each set of primers.

Bisulfite conversion was performed on 1 µg of genomic DNA by using the EpiTec
Bisulfite Kit (Cat N°59104 QIAGEN) following the manufacturer's protocol.

PCR amplification of both converted and non-converted DNA was performed using the four selected primer pairs (Table S2). For every subject we generated two pools of amplicons: one from bisulfite converted (BSC), one from non-converted DNA. Illumina paired-end sequencing was then performed by Eurofins genomics on the amplicon pools for a total of 36 Mb (60K read pairs per amplicon with 2 x 300 bp read mode).

197

Bioinformatics analyses

199 Identification and characterization of D4Z4-like sequences and D4Z4 associated 200 elements in human genome assemblies

The complete sequence of a reference D4Z4 element was obtained from the hg38 assembly in UCSC genome browser (https://genome.ucsc.edu/). Sequence similarity searches based on the BLAST program⁴⁵ were performed to annotate D4Z4-like elements and functional

204 elements of the D4Z4 array (see below), in the hg38 reference assembly of the human 205 genome [GRCh38.p14 - hg38 - Genome - Assembly - NCBI], the T2T assembly [T2T-206 CHM13v1.1 - Genome - Assembly - NCBI], and 86 distinct haplotype-level assemblies from 207 PGR, https://github.com/humanthe available from as 208 pangenomics/HPP_Year1_Assemblies. 209 Results of BLAST sequences similarity searches were stored in simple tabular format 210 and processed by custom Perl scripts. A similarity threshold of 85% and an alignment length 211 threshold of 300 aligned or more aligned residues were used to define D4Z4-like elements. 212 Matches were binned in 5 bins according to their size (<500bp; <1000bp; <1500bp; 213 <2500bp; and <3300bp). Matches of size in-between 3200 and 3300 bp were considered to provide a complete representation of a D4Z4 macrosatellite (full match). 214 215 D4Z4 arrays were annotated based on the terminal repeat for the presence of qA or qB sequence variants; presence/absence of the pLam sequence and integrity of the 216

AUUAAA polyadenylation signal (PAS). qA/B has been annotated based on the sequence of the respective probes used for the FSHD diagnostic protocol; pLam has been annotated based on the sequence reported in UCSC genome browser (<u>https://genome.ucsc.edu/</u>) (Supplemental Material and Methods).

221

222 Similarity-based clustering of D4Z4 like elements and terminal DUX4 coding 223 sequences

D4Z4-like sequences of 3200 or more bp in size (full matches) were extracted from their respective genome assemblies and aligned with Kalign⁴⁶. Conserved alignment blocks were extracted with Gblocks⁴⁷, using the following parameter: Minimum Length Of A Block: 3, Allowed Gap Positions: none. A sequence similarity matrix was computed by means of the EMBOSS distmat program⁴⁸, using the Tajima-Nei correction for multiple substitutions⁴⁹. Phenetic clustering was performed by using the NJ algorithm, as implemented by hclust()

function from the cluster package in R⁵⁰. Six distinct groups with high sequence identity were defined for the D4Z4 complete elements. D4Z4 from T2T were used to anchor/assign each group to a chromosome.

The same method was applied to cluster ter-*DUX4* coding sequences by sequence similarity. Terminal repeats were identified based on the presence of a qA or qB element *in cis* and within 15 Kb from a complete *DUX4* ORF and tentatively assigned to chr 4 or 10 based on sequence similarity.

237

In-silico identification of target regions of primer sets in hg38 and T2T genome assemblies

Potential target regions of primer sets in the hg38 and T2T genome assemblies were 240 241 determined by a custom Perl script (Table S4). Sequence similarity searches of primer 242 sequences on the hg38 and T2T reference assemblies were performed by blastn, with 243 default parameters⁴⁵. All matches of 17 bp or longer and with at most 1 mismatch and all 244 perfect matches of 16 bp or longer were recorded. Genomic coordinates were cross-245 referenced, and potential target genomic regions were identified as those spanned by a 5' 246 and 3' primer pairs, in the correct orientation, and within a distance >50 bp and <600 bp. 247 The same procedure was applied for the identification of potential primer target regions in 248 the BSC space, in this case both the genome and the primer sequences were converted in-249 silico.

250

251 Statistical analyses

Distribution of values were compared by applying the non-parametric, two tailed Kolmogorov Smirnoff test, as implemented by the ks.test() function from the stats package of the R programming language.

255

256 Analysis of bisulfite converted reads

257 **Quality control and determination of target regions**

Reads' quality was assessed by Fastqc^{51,52}. Individual reports were merged by MultiQC⁵³
and quality metrics were visually inspected.

Non-converted amplicons' reads were aligned to T2T and hg38 human genome assemblies using Bowtie2⁵⁴. Sample-level coverage profiles were computed by bedtools genomecov⁵⁵. Genomic regions covered by 100 or more reads in at least 50% of samples were considered for subsequent analyses. By this approach a total of 172 and 57 candidate target regions were identified in the T2T and hg38 assemblies, respectively. 50/57 and 169/172 had at least a high similarity match (17 bp with at most 1 mismatch) to one or more primer sequences.

267 Highly similar candidate regions were collapsed to provide a non-redundant 268 representation of repetitive sequences and allow non-ambiguous mapping of BSC reads. 269 Different sequence identity thresholds were tested through a titration analysis to identify the 270 ideal sequence similarity threshold. The total number of non-ambiguously mapped BSC 271 reads and the total number of CpGs covered by at least 10 BSC reads in at least 50% of 272 samples (testable CpGs) were recorded (Table 1). Considerations based on the number 273 and cumulative size of genomic regions that were merged, and on the number of testable 274 CpGs, prompted us to select 95% identity as the most appropriate threshold. In conclusion, 275 by comparing hg38 and T2T-based analyses of non-converted reads, we defined a total of 276 60 and 9 distinct consensus groups (groups of sequences GS) respectively (Table S5 and 277 Table S6). For every target region the consensus sequence was determined by majority 278 rule consensus, by applying the cons EMBOSS program⁴⁸. These consensus sequences 279 were used for the further analysis of methyl-seq data.

280

281 Assessment of methylation levels

BSC reads were aligned to consensus target region sequences and methylation levels were determined by Bismark⁵⁶ +Bowtie2. The bismark_methylation_extractor tool was applied to compute CpG methylation levels. Only CpGs covered by more than 10 reads in at least 25 patients were considered for the delineation of methylation profiles.

286

287 SMCHD1 variants analysis

288 FSHD2 probands are routinely tested for the presence of SMCHD1, DNMT3B, LRIF1 289 variants. We collected the identified SMCHD1 variants in the cohort and performed a 290 reannotation GRCh37 wAnnovar⁵⁷ on genome assembly using 291 (https://wannovar.wglab.org/; the analysis was performed on the 27.9.22) and filtered. We 292 excluded intron variants and considered only exonic (missense, stop or frameshift variants) 293 and splicing variants with a GnomAD exome all MAF $< 10^{-4}$ (GnomAD frequency for PM2) 294 pathogenic moderate rule in Varsome)⁵⁸. Among the filtered variants we then excluded the 295 ones which were benign and likely benign according to Varsome ACMG (American College 296 of Medical Genetics and Genomics) prediction^{59,60} (https://varsome.com/; the analysis was 297 performed on 27.9.22). As SMCHD1 gene function has not been thoroughly investigated 298 yet, we decided not to filter out the variants predicted as VUS (Variants of Uncertain 299 Significance). Finally, variant validation through Sanger sequencing was performed on 300 probands and on relatives (Table S7).

- 301
- 302 **Results**

303

T2T and PGR reveal the extended variability of D4Z4 repeats throughout the human
 genome

306 The extent of D4Z4-like repeat elements in the human genome was investigated by 307 analyzing T2T and 86 haplotype-level genome assemblies from the PGR⁴².

308 Our analyses uncovered hundreds of "complete" (>3200 bp) as well as partial (300 309 - 3200 bp) D4Z4-like sequences (hereafter D4Z4-l), irrespective of the reported geographic 310 origin of the subjects (Table S8). The cumulative size of D4Z4-I spanned in-between 700 311 Kb to 1.5 Mb of sequence in the haplotype-level assemblies of the 43 subjects from the 312 PGR and accounted for approximately 1.2 Mb of sequence in T2T. D4Z4-I were scattered 313 through several chromosomes in T2T and accounted for hundreds of kilobases of 314 sequences on chr 1, chr 4, chr 10, chr 15, chr 21 and chr 22 (Figure 2A). Notably, in hg38 315 only 86.5 Kb of D4Z4-I were observed, representing a more than 10-fold reduction 316 compared with T2T and PGR (Figure 2B). In hg38, D4Z4-I were prevalently associated with 317 the long arms of chr 4 and chr 10 (Figure 2A) where they are arranged as two large arrays of 8 and 10 complete D4Z4 repeats, respectively. PGR and T2T instead harbored a large 318 319 number (minimum 285, maximum 626, Table S8) of "incomplete" D4Z4-I repeats of < 2.5 320 Kb in size, which are lacking in hg38. Conversely (Figure 2B), the number of complete D4Z4 321 elements included in hg38 was within the range of variability observed in T2T and PGR (26 to 121). Interestingly, subjects from AFR (African) ancestry were associated with a higher 322 323 variability in D4Z4-I copy numbers (Kolmogorov Smirnoff test p-value p-value = 0.0006403), 324 while a narrower range was observed in individuals of EAS (Eastern Asia) and AMR (South 325 America) ancestry (Figure S3).

326 Figure 2C shows the variability and the distribution of complete D4Z4-I elements. Six 327 different groups were defined on the basis of sequence identity levels. D4Z4 from T2T were 328 used to anchor/assign each group to a chromosome. The largest clusters (Table 2) and the 329 majority of the sequences (87%) were assigned to either chr 4 (cluster-2) or chr 10 (cluster-330 1); this notwithstanding, complete D4Z4 elements were also observed on chr 14 (cluster-3), 331 chr 22 (cluster-5 and cluster-6), chr 15 and chr 21 (cluster-4). The number of complete D4Z4 elements assigned to distinct clusters in the 86 PGR haplotypes is summarized in Figure 332 333 2D and Table 2. Chr 4 and chr 10 were associated with a median number of 22 and 19

334 repeats, respectively. The difference was statistically significant according to a Kolmogorov 335 Smirnov test (p-value: 0.02518). Complete D4Z4 repeats on chr 10 displayed lower 336 variability compared with those on chr 4. Substitution rates estimates at haplotype levels 337 suggested a high inter-individual variability, with rates ranging from 0.164 to 0.4312 338 (average of 0.245) substitutions for 100 bp for chr 4 and from 0.015 to 0.21 (average of 339 0.13) for chr 10 (Figure S4 and Figure S5). Interestingly, as shown in Table 2, more than 340 75% of the assemblies carried D4Z4-I assigned to cluster-6 (chr 22); whereas less than 50% 341 of the haplotype assemblies in the PGR had one sequence assigned to cluster-3 (chr 14), 342 cluster-4 (chr 15-21) and cluster-5 (chr 22).

343

344 The pangenome assemblies show the high frequency of the 4qA-PAS haplotype 345 associated with FSHD in the world population

The permissive DRA 4qA-PAS haplotype has been proposed to cause FSHD. However, we previously reported a frequency of 2% for this haplotype³⁸, which is not compatible with the prevalence of the disease⁶¹. We thus analyzed the T2T and PGR to investigate the prevalence of this molecular signature in other populations and to study the conservation and the integrity of ter-*DUX4*.

351 The pLam and telomeric qA and qB sequences (Supplemental Material and Methods) were used to identify and classify terminal D4Z4 repeat in PGR, T2T and hg38. A 352 353 total of 172 D4Z4 terminal repeats were identified (Table S9) and tentatively assigned to chr 354 4 or chr 10 based on sequence similarity profiles (as described by the clustering of the 355 D4Z4-I sequences in Figure 2C). Haplotypes with inconsistent annotations (2 or more gA/gB 356 probes assigned to the same chromosome and none to the other chromosome) were not 357 included in subsequent analysis^{62,63}. By this approach the complete set of alleles at D4Z4 repeat loci at chr 4 and chr 10 was determined for 72 haplotypes from PGR (Table S9). 358 359 Patterns of conservation of ter-DUX4 sequences were investigated. Figure 3A shows that

360 ter-DUX4 assigned to the 10g D4Z4 terminal repeat are found to be highly similar and 361 formed a single cluster; while 4q ter-DUX4 are more heterogeneous and were partitioned in 3 groups (Figure 3A-B). Interestingly, as shown in Figure 3C, in chr 10 and chr4 group 2 362 363 ter-DUX4 displayed lower levels of variability (average 0.061 subs per 100 bp) compared to 364 both chr4 group 3 (average 0.12 subs per 100 bp) and chr4 group 1 (average 0.142 subs 365 per 100 bp); Figure 3A also shows that the most variable sequences (chr4 group 1 and 366 chr4_group 3) were preferentially associated with qB alleles. All ter-DUX4 sequences were 367 found to be intact, and none was associated with frameshifts or premature stop codons. Consistent with previous observations^{18,19}, all the alleles classified as qB did not carry a 368 369 pLam and were more proximal to the ter-DUX4 compared to qA (Figure 3D-G). In the same 370 way, (Figure 3E-F) the vast majority of alleles classified as qA (112/119) were associated 371 with a pLam both on chr 4 (41/47) and chr 10 (71/72). Only terminal 4q pLam had valid 372 PAS⁶⁴; while in pLam assigned to 10q the PAS sequences were disrupted by a single nucleotide substitution (AUUAAA→AUCAAA). Perfect conservation of PAS/PAS-like 373 374 elements was observed both on 4q and 10q terminal D4Z4 repeats. One qB haplotype was 375 assigned to 10q (Table 3).

Remarkably, in line with our previous observations^{38–40} (Table 3), 4/86 haplotypes (4.6%) carried D4Z4 alleles with 6-8 RU and 4qA-PAS (Figure 3F). None of these haplotypes carried disruptive variants in the ter-*DUX4* or in the pLam sequence element.

No statistically significant difference in the total number of chr 4 D4Z4 repeats was observed when qA/qB alleles pLam+/pLam- alleles were compared (Figure 3H-I), suggesting that alleles that are not permissive for the expression of the ter-*DUX4* are not associated with significant differences in D4Z4 copy numbers compared with the permissive qA-PAS haplotype.

384

385 **D4Z4** hypomethylation correlates with SMCHD1 damaging variants but not with FSHD

386 clinical phenotype

Results shown above uncover all the heterogeneity of D4Z4 repeats in the human genome, including the presence of qA D4Z4 alleles with 8 repeats or fewer, and raise potential concerns about the reliability of methylation/diagnostic tests based on the hg38. As bisulfite treated DNA sequencing at targeted regions is commonly used to diagnose FSHD⁶⁵, the uncovered variability of D4Z4-I sequences prompted us to investigate D4Z4 CpG methylation comparing the hg38 and the T2T.

A set of primers spanning the entire length of the D4Z4 repeat and a total of 126 CpGs (Figure S2 and Table S3) were designed based on hg38 assembly to recapitulate previous findings in the field⁴¹. This experimental design was used to assess a carefully selected cohort of 26 index cases referred for FSHD2 diagnosis, and 14 relatives all carrying 10 or more RU. All the participants assayed were searched for damaging variants in the chromatin remodelers *SMCHD1, DNMT3B* and *LRIF1*. In addition, 3 FSHD1 index cases and 1 relative carrying 4 RU were studied.

Amplicon targeted regions were sequenced both in non-converted and in BSC DNA samples. This approach was undertaken: i. to test the 4q/10q-specificity of the primer sets commonly used and designed based on hg38 assembly⁴¹, ii. to facilitate the alignment of short BSC derived reads. Both non-converted and BSC NGS data were used for sequence alignment based on hg38 and T2T reference genomes (Table S4).

A total of 77% and 99.43% non-converted short reads mapped to hg38 and T2T respectively. Moreover, the majority of BSC reads (62% for T2T and 54% for hg38) did not align at 4q primer target regions, potentially suggesting "off target" sequences, and/or high levels of heterogeneity in methylation levels. To identify genomic regions targeted by our assay in an unbiased manner, genomic intervals covered by 100 or more non-converted reads in at least 50% of the samples were recorded. A total of 57 and 172 genomic regions

411 in hg38 and T2T displayed these remarkable levels of coverage. Notably, 50/57 and 412 169/172 of the target regions delineated by coverage analyses had at least a high similarity 413 match (17 bp with at most 1 mismatch) to one or more primer sequences. Based on these 414 observations sequences above 95% sequence similarity were collapsed to prevent 415 inconsistent mapping of BSC short reads across highly similar D4Z4-I elements. By this 416 approach, we defined a total of 60 and 9 distinct consensus groups (groups of sequences, 417 hereafter GS) in T2T and hg38 respectively (Table S5 and Table S6). Consensus 418 sequences were computed for each GS and used for the further analysis of methyl-seq 419 data.

420 This ad-hoc bioinformatics workflow revealed remarkable differences in the completeness, number, and breadth of testable CpGs when the GSs derived from hg38 and 421 422 T2T were compared: hg38 125 CpG; T2T 938 CpG. Global methylation patterns were 423 summarized in the form of a heatmap (Figure S6 and Figure S7). In the T2T-based analysis 424 a total of 4 distinct GS including 81 distinct CpGs had no missing data and complete 425 methylation profiles across all samples, as shown in Figure 4 and Table 4: GS1 (primer D6): 426 28 CpGs; GS2 (primer D1): 32 CpGs; GS5 (chr 13-chr 15): 16 CpGs and GS6 (chr 13-chr 427 15): 5 CpGs). Notably, only GS1 and GS2 included D4Z4 5' 4q/10q-specific regions 428 exclusively, for a total of 60 CpGs, while GS5 and GS6 mapped in D4Z4-I repeats on chr 429 13 and 15. The wide-range distributions of CpG methylation levels, as displayed in Figure 430 S8, highlight a high variability at regions GS1 and GS2, while off-target regions GS5 and 431 GS6 have high methylation levels, with a narrower distribution. Figure S9 shows a general 432 overview of the CpG methylation patterns observed in all the 60 distinct GSs defined in our 433 analysis. Taken together these findings indicate that a significant proportion of the BSC 434 reads recovered by our targeted high throughput assay derive from off-target, hypermethylated D4Z4-I regions. We also observed that when hg38 is considered as reference, 435 436 the criteria we established for the T2T-based analysis (namely no missing data and

437 complete methylation profiles across all samples) identified only a single group, GS3 (primer 438 D1) including 26 CpGs (Figure 4, Figure 5 and Table 4). In the light of these observations, 439 methylation profiles inferred from T2T were considered more informative and were selected 440 for subsequent analyses. Only primer D1 had complete data both in T2T and hg38 (Table 441 4); however, CpG methylation levels estimated on hg38 were slightly more elevated 442 compared to those observed on T2T at the equivalent target region (Figure S10, median 443 values: 49.13 hg38, 43.75 T2T). An observation that might be consistent with discrepancies 444 in the mapping of BSC reads on different genome assemblies.

Further, our analysis revealed that 4q/10q-specific methylation patterns at GS1 and GS2 stratified samples into 3 groups: low methylation (average CpG methylation 24%), intermediate methylation (average CpG methylation 48%), and high methylation (average CpG methylation 71%). The methylation pattern of GS5 and GS6 was highly uniform across all samples, with an average of 89%.

Interestingly, the observed methylation profiles did not correlate with the disease 450 451 status. As shown in Figure 6A, of 16 samples presenting low methylation 10 (62.5%) derived 452 from cases presenting the classical FSHD features (CCEF category A), 6 (37,5%) derived 453 from cases presenting incomplete (2, CCEF clinical Category B) or complex (4, CCEF 454 clinical category D) phenotypes. Of 16 samples, presenting intermediate methylation 9 (56.3%) derived from cases assessed as clinical category A. Of 12 samples presenting high 455 456 methylation 7 were from Category A cases (58.3%). Consistently, the methylation level 457 distributions assessed in DNA from subjects presenting the CCEF clinical categories A, B 458 and D was not statistically different (Figure S11). Instead, the majority (11/16) of participants 459 in the low methylation group carried Pathogenic, Likely Pathogenic variants or Variants of 460 Uncertain Significance according to ACMG classification⁶⁰ (P/LP/VUS variants) in SMCHD1 (Fisher exact test p-value 0.0003). This association was confirmed by the comparison of the 461 methylation profile distributions of SMCHD1 P/LP/VUS variants carriers and non-carriers 462

463 (Figure 4, Kolmogorov-Smirnov test p-value <= 1e-16). Identical patterns were recovered
464 also when methylation levels on the hg38 assembly were assessed with our approach
465 (Figure 5).

466

467 **Discussion**

468

The pangenome assemblies provide novel hints to evaluate the significance of the D4Z4-like sequences in the clinical setting

471 Thirty years ago, reduction below a critical threshold of the number of repeats belonging to the D4Z4 macrosatellite at 4q35 was causally associated with FSHD. D4Z4 is part a family 472 473 of repetitive elements characteristic of heterochromatin and it was then known that many 474 D4Z4-I were present in the human genome⁶⁶. At that time, the lack of a complete genome 475 assembly hampered the possibility of fully deciphering the significance of molecular and 476 epigenetic findings in FSHD. Very recently, these limitations have been overcome by the 477 availability of complete, high quality haplotype level genome assemblies. By analyzing the 478 haplotypes from the PGR we collected relevant information on the size, the distribution and 479 the composition of the D4Z4 locus, including distal sequence elements that are considered a hallmark of the FSHD molecular signature. We established that the number of 3.3 kb D4Z4 480 481 repeats included in each array ranges from 6 RU to 89 RU⁴⁰. We observed that the distance 482 between the qA sequences and the last D4Z4 repeat varies. We also confirmed that qA 483 sequences are more distal compared to gB sequences; the pLam sequence is in association with qA haplotypes¹⁸, and valid PAS is exclusively associated with 4q⁶⁴; chr 10 D4Z4 484 485 repeats were all marked by qA, with a single exception: a 10qB allele carrying 1 RU. Notably, 486 PGR haplotype analysis confirmed the high frequency of the permissive 4qA-PAS haplotype, which is comparable to a common polymorphism⁶¹. In fact, in 4.6% of cases we 487 identified permissive haplotypes consisting of reduced 4g D4Z4 arrays with \leq 8 RU and the 488

489 4qA-PAS. Since all ter-DUX4 and pLam sequence elements associated with 4qA alleles 490 were found to be conserved and functionally intact, we speculate that disruptive genomic 491 variants at the ter-DUX4 are unlikely to account for the staggering discrepancy between the 492 frequency of the presumed causative 4qA-PAS allele and the prevalence of FHSD. 493 Furthermore, no skewed association has been detected between 4g D4Z4 arrays copy 494 number and qA/B alleles¹⁹, indicating that non-permissive 4qB alleles and potentially 495 permissive 4qA alleles do not have a different selective pressure for the mainteinance of 496 the physiological number of D4Z4 RU.

The consistency between data obtained from the analysis of PGR and previous observations^{6,61,66} shows the validity of the PGR to advance knowledge of the molecular signature used to diagnose FSHD on a world-wide scale.

The PGR analysis also identified 6 haplotypes with peculiar annotations where 2 or more qA/qB probes were assigned to the same chromosome and none to the other chromosome (Table S9). This condition has been reported before⁶² and is ascribable to the spreading of repetitive and polymorphic D4Z4-I at different loci of the genome^{63,67}.

504 Our comparative analyses of complete D4Z4-I (Figure 2C) highlighted that D4Z4 505 repeats, as well as the ter-*DUX4*, located at chr 4 present a higher variability compared to 506 chr 10. In addition, PGR haplotypes from different ancestries showed different levels of 507 variability in the number of complete D4Z4-I, with a significant difference in D4Z4 copy 508 number between individuals of African ancestry, native Americans and far east Asians.

509

510 **D4Z4 methylation assay must consider the T2T sequence for the identification of** 511 **4q/10q-specific CpGs**

512 Reduced CpG methylation at D4Z4 has been widely studied and proposed as a biomarker 513 for the presence of FSHD. Previous studies of D4Z4 methylation presented some 514 drawbacks: technical limitations and lack of reproducibility led to discordant results

515 regarding which regions are the most representative for D4Z4 methylation status^{20,32,68–74}. 516 In addition, the correlation between D4Z4 methylation level and FSHD clinical status has 517 often been postulated, but different technical settings in the various studies, the lack of clear 518 clinical evaluation of patients and the prominent absence of family studies had hindered the 519 interpretation of results^{20,41,73,74}. In the present work, we comprehensively evaluated the 520 D4Z4 methylation status by considering a high number of reads and excluding technical 521 biases introduced by the previous studies based on hg38 and on standard bioinformatics 522 pipelines. We established (Figure S2) that the primer sets BSS-D1 and BSS-D6 identify 523 CpG methylation signals deriving from 4q/10q-specific regions only, whereas the primer 524 sets BSS-D3 and BSS-D5 amplify D4Z4-I distributed not only at 4g and 10g but also on 525 chromosome 1 and on the short arms of acrocentric chromosomes. Thus, the study of D4Z4 526 CpG methylation can be hazardous if the distribution of D4Z4-I elements and their variability 527 are not correctly taken into account.

528 Despite all this, the application of short read-based assays for the analysis of 529 repetitive elements of relatively large size has limitations. When non-converted reads were 530 aligned to both hg38 and T2T, more than 50% of mapped reads did not align at expected target regions. Nevertheless, the total fraction of mapped reads and the number of testable 531 532 CpGs were higher when aligned to T2T compared to hg38, confirming that T2T provides a 533 more accurate representation of the human genome. We can anticipate that long read 534 sequencing technologies, such as Oxford Nanopore, will provide relevant technical 535 advances and open new possibilities for the study of repetitive elements' organization and 536 function in the genome. In this respect, Butterfield and colleagues (2023)⁷⁵ applied targeted 537 nanopore sequencing to FSHD patients and healthy subjects and showed that an 538 asymmetric methylation gradient forms in a length-dependent manner at the proximal end 539 of the D4Z4 repeat array reaching saturation approximately at the 10th repeat. They also 540 observed a highly similar methylation pattern at 4g and 10g which was irrespective of the

clinical phenotype (FSHD or healthy)⁷⁵. This notwithstanding, at present, long-read sequencing technologies are not mature for systematic large-scale applications in the clinical settings. Instead, the targeted CpG methylation analysis we set up is manageable on a large scale as it follows a simple protocol, is less expensive and highly reproducible. Remarkably, our data are consistent with the results obtained by Butterfield and colleagues.

546

547 **D4Z4 CpG methylation level is not a predictor of FSHD disease**

548 Beside the formal demonstration that primer design is a crucial point in the analysis of D4Z4 549 methylation, our study also revealed that contrary to common knowledge²⁰, not all DNAs 550 from myopathic patients referred as FSHD2 (26 index cases) presented a low methylation 551 level. Our analysis identified three clusters with low, intermediate and high D4Z4 CpG 552 methylation (mean at 24%, 48% and 71% respectively). Figure 6 depicts the results of 553 several comparisons regarding the following parameters: clinical phenotype, D4Z4 554 methylation level and SMCHD1 mutational status. Figure 6A shows that some genotype-555 phenotype intersections are not in agreement with the current indications for FSHD 556 diagnosis^{76,77}. Remarkably, we observed the full range of D4Z4 methylation levels in DNA from the 26 participants presenting a classical FSHD phenotype (CCEF Clinical Category 557 558 A); of those 16 carriers of a damaging SMCHD1 variant, 11 presented low 4q/10q-specific 559 D4Z4 CpG methylation, 5 displayed intermediate CpG methylation. We also observed 5 560 samples with low CpG methylation with no damaging SMCHD1 or DNMT3B or LRIF1 561 variants and presenting classical (2), incomplete (1) or complex (2) phenotypes. underlying 562 the genetic heterogeneity of this molecular phenotype.

563 The variants we identified were distributed all along *SMCHD1* gene body and did not 564 provide information on specific SMCHD1 region/domain that might account for the reduced 565 methylation at 4q/10q-specific D4Z4 sequences (Figure 6B).

566 To further explore this aspect, we investigated genotype-phenotype correlation in 567 eight trios/parent-child pairs participating to this study (Figure 6C, Table S7). We observed 568 participants presenting the classical FSHD phenotype (CCEF Category A), healthy subjects 569 (CCEF Category C) or complex phenotypes presenting atypical features (CCEF Category 570 D). According to our data, only in families 1 and 26 subjects presenting a classic FSHD 571 phenotype displayed a reduced CpG methylation profile and carried a damaging 572 heterozygous SMCHD1 variant. In family 22 the classic clinical phenotype, in presence of 573 D4Z4 reduced methylation, was not associated with variants in known chromatin modifiers. 574 In family 8 the probands presented the classic clinical phenotype associated with 575 intermediate D4Z4 methylation level in presence of a damaging SMCHD1 variant, as the 576 healthy mother. In family 27 the proband presented the Category A phenotype associated 577 with reduced CpG methylation and a damaging SMCHD1 variant, whereas intermediate 578 D4Z4 methylation level was detected in the healthy father carrying the same SMCHD1 579 allele. In family 30 father and daughter presented a complex phenotype with atypical clinical 580 symptoms (Category D1); both reported clinical onset at pelvic girdle and distal lower limbs. 581 They were heterozygous for SMCHD1 damaging variant and presented reduced D4Z4 CpG 582 methylation. In families 9 both the probands and her father presented Category A phenotype 583 without displaying reduced D4Z4 CpG methylation and carrying WT SMCHD1 alleles, as the proband in family 11. 584

Altogether, these results suggest that SMCHD1 modulates, directly or indirectly, D4Z4 methylation at 4q and 10q, at the same time it seems that deleterious variants at *SMCHD1* are not sufficient for the pathogenesis of FSHD and cannot be considered faithful indicators of FSHD clinical status.

In conclusion, our work uncovered the complexity of the genomic setting of D4Z4-I and showed that a molecular diagnostic test for FSHD2 based on *SMCHD1* inactivation and D4Z4 hypomethylation must follow rigorous protocols to avoid biased interpretation.

592 Molecular analysis should be considered together with precise clinical assessment and 593 complemented by family studies for the proper interpretation of results. Moreover, the 594 variability unveiled by our analysis should warn about the risk of relying on a single ideal 595 reference genome sequence in FSHD. In fact, this simplification could strongly narrow our 596 capacity of observing the variability ascribable to each single human genome producing 597 biased interpretations of sequencing data. Finally, our study indicates that a linear approach 598 to diagnose FSHD is obsolete and novel genomic approaches integrated with the precise 599 phenotypic description of patients and their families are needed for the comprehension of 600 the molecular network leading to muscle wasting in FSHD.

601

602 **Declarations**

603

604 Acknowledgements

We are grateful to Francesca Brocco for contributing to the molecular analysis. In addition, we are indebted to all FSHD patients and their families for participating in this study. We acknowledge the Fondazione di Modena for FAR-FOMO 2021 grant funding this work.

608

609 Authors' contributions

RGT, VS, MC conceived the study concept and supervised the project; VS, SP conducted the molecular analysis; MC conducted bioinformatics analysis; PK and MK contributed to bioinformatic analysis; LR, SCP, MGD, CR, SB, LM, DL contributed to the patients clinical analysis and sample collection; FMS, GP contributed to results discussion; RGT, VS, MC, SP wrote the paper (original draft); all authors read and approved the final manuscript.

616 **Declaration of interests**

617 The authors declare no competing interests.

618

619 Web sources

- 620 The PGR dataset analyzed during the current study is available at
- 621 <u>https://github.com/human-pangenomics/HPP_Year1_Assemblies</u>.
- 622

623 Availability of data and materials

- 624 Data generated and/or analyzed during the current study and not included in this
- 625 published article are available from the corresponding author on reasonable request.
- 626

627 Ethics approval and consent to participate

- 628 Signed informed consent was obtained from all the subjects prior to the inclusion in the
- 629 study. The study was approved by the ethics committee of Emilia Romagna Area Vasta

630 Nord 743/2022/OSS/UNIMO SIRER ID 5111.

631

632 **References**

- Deenen, J.C.W., Arnts, H., Van Der Maarel, S.M., Padberg, G.W., Verschuuren, J.J.G.M.,
 Bakker, E., Weinreich, S.S., Verbeek, A.L.M., and Van Engelen, B.G.M. (2014). Population based incidence and prevalence of facioscapulohumeral dystrophy. Neurology *83*, 1056–
 1059. 10.1212/WNL.00000000000797.
- 638 2. Mostacciuolo, M.L., Pastorello, E., Vazza, G., Miorin, M., Angelini, C., Tomelleri, G., Galluzzi,
 639 G., and Trevisan, C. Pietro (2009). Facioscapulohumeral muscular dystrophy:
 640 Epidemiological and molecular study in a north-east Italian population sample. Clinical
 641 Genetics 75, 550–555. 10.1111/j.1399-0004.2009.01158.x.
- 642 3. Dumbovic, G., Forcales, S. V., and Perucho, M. (2017). Emerging roles of macrosatellite
 643 repeats in genome organization and disease development. Epigenetics *12*, 515–526.
 644 10.1080/15592294.2017.1318235.
- 4. Lunt, P.W. (1998). 44th ENMC International Workshop: Facioscapulohumeral muscular
 dystrophy: Molecular studies, 19-21 July 1996, Naarden, The Netherlands. Neuromuscular
 Disorders *8*, 126–130. 10.1016/S0960-8966(98)00012-1.

- 648 5. Hewitt, J.E., Lyle, R., Clark, L.N., Valleley, E.M., Wright, T.J., Wijmenga, C., Van Deutekom, J.C.
 649 t., Francis, F., Sharpe, P.T., Hofker, M., et al. (1994). Analysis of the tandem repeat locus
 650 D4Z4 associated with facioscapulohumeral muscular dystropothhy. Human Molecular
 651 Genetics *3*, 1287–1295. 10.1093/hmg/3.8.1287.
- 6. Winokur, S.T., Bengtsson, U., Feddersen, J., Mathews, K.D., Weiffenbach, B., Bailey, H.,
 Markovich, R.P., Murray, J.C., Wasmuth, J.J., Altherr, M.R., et al. (1994). The DNA
 rearrangement associated with facioscapulohumeral muscular dystrophy involves a
 heterochromatin-associated repetitive element: Implications for a role of chromatin
 structure in the pathogenesis of the disease. Chromosome Research *2*, 225–234.
 10.1007/BF01553323.
- 7. Zhang, X.Y., Loflin, P.T., Gehrke, C.W., Andrews, P.A., and Ehrlich, M. (1987).
 Hypermethylation of human DNA sequences in embryonal carcinoma cells and somatic
 tissues but not in sperm. Nucleic Acids Research *15*, 9429–9449.
 10.1093/nar/15.22.9429.
- 8. Agresti, A., Meneveri, R., Siccardi, A.G., Marozzi, A., Corneo, G., Gaudi, S., and Ginelli, E.
 (1989). Linkage in human heterochromatin between highly divergent Sau3A repeats and
 a new family of repeated DNA sequences (HaeIII family). Journal of Molecular Biology *205*,
 625–631. 10.1016/0022-2836(89)90308-2.
- Meneveri, R., Agresti, A., Marozzi, A., Saccone, S., Rocchi, M., Archidiacono, N., Corneo, G.,
 Valle, G.D., and Ginelli, E. (1993). Molecular organization and chromosomal location of
 human GC-rich heterochromatic blocks. Gene *123*, 227–234. 10.1016/03781119(93)90128-P.
- 10. Deidda, G., Cacurri, S., Grisanti, P., Vigneti, E., Piazzo, N., and Felicetti, L. (1995). Physical
 mapping evidence for a duplicated region on chromosome 10qter showing high homology
 with the facioscapulohumeral muscular dystrophy locus on chromosome 4qter. European
 Journal of Human Genetics *3*, 155–167. 10.1159/000472291.
- 11. Deutekom, J.C.T. van, Wljmenga, C., Tlenhoven, E.A.E. van, Gruter, A.M., Hewitt, J.E.,
 Padberg, G.W., van Ommen, G.J.B., Hofker, M.H., and Fronts, R.R. (1993). FSHD associated
 DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated
 unit. Human Molecular Genetics *2*, 2037–2042. 10.1093/hmg/2.12.2037.
- 678 12. Gabellini, D., Green, M.R., and Tupler, R. (2002). Inappropriate gene activation in FSHD: A
 679 repressor complex binds a chromosomal repeat deleted in dystrophic muscle. Cell *110*,
 680 339–348. 10.1016/S0092-8674(02)00826-7.
- 13. Cabianca, D.S., Casa, V., Bodega, B., Xynos, A., Ginelli, E., Tanaka, Y., and Gabellini, D.
 (2012). A long ncRNA links copy number variation to a polycomb/trithorax epigenetic
 switch in fshd muscular dystrophy. Cell *149*, 819–831. 10.1016/j.cell.2012.03.035.
- Laoudj-Chenivesse, D., Carnac, G., Bisbal, C., Hugon, G., Bouillot, S., Desnuelle, C., Vassetzky,
 Y., and Fernandez, A. (2005). Increased levels of adenine nucleotide translocator 1 protein
 and response to oxidative stress are early events in facioscapulohumeral muscular
 dystrophy muscle. Journal of molecular medicine (Berlin, Germany) *83*, 216–224.
 10.1007/s00109-004-0583-7.

- 15. Lemmers, R.J.L.F., Tawil, R., Petek, L.M., Balog, J., Block, G.J., Santen, G.W.E., Amell, A.M.,
- Lemmers, R.J.L.F., Tawil, R., Petek, L.M., Balog, J., Block, G.J., Santen, G.W.E., Amell, A.M.,
 Vliet, P.J. Van Der, Almomani, R., Straasheijm, R., et al. (2012). Digenic inheritance of an
 SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral
 muscular dystrophy type 2. Nat Genet. 44, 1370–1374. 10.1038/ng.2454.Digenic.
- 16. Van Den Boogaard, M.L., Lemmers, R.J.L.F., Balog, J., Wohlgemuth, M., Auranen, M.,
 Mitsuhashi, S., Van Der Vliet, P.J., Straasheijm, K.R., Van Den Akker, R.F.P., Kriek, M., et al.
 (2016). Mutations in DNMT3B Modify Epigenetic Repression of the D4Z4 Repeat and the
 Penetrance of Facioscapulohumeral Dystrophy. American Journal of Human Genetics *98*,
 1020–1029. 10.1016/j.ajhg.2016.03.013.
- 17. Hamanaka, K., Šikrová, D., Mitsuhashi, S., Masuda, H., Sekiguchi, Y., Sugiyama, A., Shibuya,
 K., Lemmers, R.J.L.F., Goossens, R., Ogawa, M., et al. (2020). Homozygous nonsense variant
 in LRIF1 associated with facioscapulohumeral muscular dystrophy. Neurology *94*, E2441–
 E2447. 10.1212/WNL.00000000009617.
- 18. Van Geel, M., Dickson, M.C., Beck, A.F., Bolland, D.J., Frants, R.R., Van der Maarel, S.M., De
 Jong, P.J., and Hewitt, J.E. (2002). Genomic analysis of human chromosome 10q and 4q
 telomeres suggests a common origin. Genomics *79*, 210–217. 10.1006/geno.2002.6690.
- 19. Lemmers, R.J.L.F., de Kievit, P., Sandkuijl, L., Padberg, G.W., van Ommen, G.J.B., Frants, R.R.,
 and van der Maarel, S.M. (2002). Facioscapulohumeral muscular dystrophy is uniquely
 associated with one of the two variants of the 4q subtelomere. Nature Genetics *32*, 235–
 236. 10.1038/ng999.
- 20. Gould, T., Jones, T.I., and Jones, P.L. (2021). Precise epigenetic analysis using targeted
 bisulfite genomic sequencing distinguishes fshd1, fshd2, and healthy subjects. Diagnostics
 11, 1–17. 10.3390/diagnostics11081469.
- 712 21. Ricci, G., Scionti, I., Sera, F., Govi, M., D'Amico, R., Frambolli, I., Mele, F., Filosto, M., Vercelli,
 713 L., Ruggiero, L., et al. (2013). Large scale genotype-phenotype analyses indicate that novel
 714 prognostic tools are required for families with facioscapulohumeral muscular dystrophy.
 715 Brain *136*, 3408–3417. 10.1093/brain/awt226.
- 716 22. K Goto, I Nishino, Y.K.H. (2004). Very low penetrance in 85 Japanese families with
 717 facioscapulohumeral muscular dystrophy 1A K. J Med Genet *41*.
 718 10.4324/9780203994559-14.
- 23. Wu, Z.Y., Wang, Z.Q., Murong, S.X., and Wang, N. (2004). FSHD in Chinese population:
 Characteristics of translocation and genotype-phenotype correlation. Neurology *63*, 581–
 583. 10.1212/01.WNL.0000133210.93075.81.
- 722 24. Nikolic, A., Ricci, G., Sera, F., Bucci, E., Govi, M., Mele, F., Rossi, M., Ruggiero, L., Vercelli, L.,
 723 Ravaglia, S., et al. (2016). Clinical expression of facioscapulohumeral muscular dystrophy
 724 in carriers of 1-3 D4Z4 reduced alleles: Experience of the FSHD Italian National Registry.
 725 BMJ Open *6*, 1–10. 10.1136/bmjopen-2015-007798.
- 726 25. Nakagawa, M., Matsuzaki, T., Higuchi, I., Fukunaga, H., Inui, T., Nagamitsu, S., Yamada, H.,
 727 Arimura, K., and Osame, M. (1997). Facioscapulohumeral Muscular Dystrophy: Clinical
 728 Diversity and Genetic Abnormalities in Japanese Patients. Internal Medicine *36*, 333–339.
 729 10.2169/internalmedicine.36.333.

- 26. Sakellariou, P., Kekou, K., Fryssira, H., Sofocleous, C., Manta, P., Panousopoulou, A.,
 Gounaris, K., and Kanavakis, E. (2012). Mutation spectrum and phenotypic manifestation
 in FSHD Greek patients. Neuromuscular Disorders *22*, 339–349.
- 733 10.1016/j.nmd.2011.11.001.
- 27. Salort-Campana, E., Nguyen, K., Bernard, R., Jouve, E., Solé, G., Nadaj-Pakleza, A.,
 Niederhauser, J., Charles, E., Ollagnon, E., Bouhour, F., et al. (2015). Low penetrance in
 facioscapulohumeral muscular dystrophy type 1 with large pathological D4Z4 alleles: A
 cross-sectional multicenter study. Orphanet Journal of Rare Diseases *10*, 4–11.
- 738 10.1186/s13023-014-0218-1.
- Ricci, G., Ruggiero, L., Vercelli, L., Sera, F., Nikolic, A., Govi, M., Mele, F., Daolio, J., Angelini,
 C., Antonini, G., et al. (2016). A novel clinical tool to classify facioscapulohumeral muscular
 dystrophy phenotypes. Journal of Neurology *263*, 1204–1214. 10.1007/s00415-0168123-2.
- 29. Lamperti, C., Fabbri, G., Vercelli, L., D'Amico, R., Frusciante, R., Bonifazi, E., Fiorillo, C.,
 Borsato, C., Cao, M., Servida, M., et al. (2010). A standardized clinical evaluation of patients
 affected by facioscapulohumeral muscular dystrophy: The FSHD clinical score. Muscle and
 Nerve 42, 213–217. 10.1002/mus.21671.
- 30. Ruggiero, L., Mele, F., Manganelli, F., Bruzzese, D., Ricci, G., Vercelli, L., Govi, M., Vallarola,
 A., Tripodi, S., Villa, L., et al. (2020). Phenotypic Variability Among Patients With D4Z4
 Reduced Allele Facioscapulohumeral Muscular Dystrophy. JAMA network open *3*,
 e204040. 10.1001/jamanetworkopen.2020.4040.
- 31. Vercelli, L., Mele, F., Ruggiero, L., Sera, F., Tripodi, S., Ricci, G., Vallarola, A., Villa, L., Govi,
 M., Maranda, L., et al. (2021). A 5-year clinical follow-up study from the Italian National
 Registry for FSHD. Journal of Neurology *268*, 356–366. 10.1007/s00415-020-10144-7.
- 32. Nikolic, A., Jones, T.I., Govi, M., Mele, F., Maranda, L., Sera, F., Ricci, G., Ruggiero, L., Vercelli,
 L., Portaro, S., et al. (2020). Interpretation of the epigenetic signature of
 facioscapulohumeral muscular dystrophy in light of genotype-phenotype studies.
 International Journal of Molecular Sciences *21*. 10.3390/ijms21072635.
- 758 33. Ricci, G., Cammish, P., Siciliano, G., Tupler, R., Lochmuller, H., and Evangelista, T. (2019).
 759 Phenotype may predict the clinical course of facioscapolohumeral muscular dystrophy.
 760 Muscle and Nerve *59*, 711–713. 10.1002/mus.26474.
- 34. Ricci, G., Mele, F., Govi, M., Ruggiero, L., Sera, F., Vercelli, L., Bettio, C., Santoro, L., Mongini,
 T., Villa, L., et al. (2020). Large genotype-phenotype study in carriers of D4Z4 borderline
 alleles provides guidance for facioscapulohumeral muscular dystrophy diagnosis.
 Scientific Reports *10*, 1–12. 10.1038/s41598-020-78578-7.
- 35. He, J.J., Lin, X.D., Lin, F., Xu, G.R., Xu, L.Q., Hu, W., Wang, D.N., Lin, H.X., Lin, M.T., Wang, N., et
 al. (2018). Clinical and genetic features of patients with facial-sparing
 facioscapulohumeral muscular dystrophy. European Journal of Neurology 25, 356–364.
 10.1111/ene.13509.
- 36. Wang, Z., Qiu, L., Lin, M., Chen, L., Zheng, F., Lin, L., Lin, F., Ye, Z., Lin, X., He, J., et al. (2022).
 Prevalence and disease progression of genetically-confirmed facioscapulohumeral
 muscular dystrophy type 1 (FSHD1) in China between 2001 and 2020: a nationwide

- 772 population-based study. The Lancet regional health. Western Pacific 18, 100323. 773 10.1016/j.lanwpc.2021.100323.
- 774 37. Salsia, V., Vattemi, G.N.A., and Tupler, R.G. (2023). The FSHD jigsaw: are we placing the tiles in the right position? Curr Opin Neurol. 10.1097/WCO.000000000001176. 775
- 38. Wohlgemuth, M., Lemmers, R.J., Van der Kooi, E.L., Van der Wielen, M.J., Van Overveld, P.G., 776 Dauwerse, H., Bakker, E., Frants, R.R., Padberg, G.W., and Van der Maarel, S.M. (2003). 777 778 Possible phenotypic dosage effect in patients compound heterozygous for FSHD-sized 779 4q35 alleles. Neurology 61, 909–913. 10.1212/WNL.61.7.909.
- 780 39. Scionti, I., Greco, F., Ricci, G., Govi, M., Arashiro, P., Vercelli, L., Berardinelli, A., Angelini, C., 781 Antonini, G., Cao, M., et al. (2012). Large-scale population analysis challenges the current 782 criteria for the molecular diagnosis of fascioscapulohumeral muscular dystrophy. 783 American Journal of Human Genetics 90, 628–635. 10.1016/j.ajhg.2012.02.019.
- 784 40. Van Overveld, P.G.M., Lemmers, R.J.F.L., Deidda, G., Sandkuijl, L., Padberg, G.W., Frants, 785 R.R., and Van Der Maarel, S.M. (2000). Interchromosomal repeat array interactions between chromosomes 4 and 10: A model for subtelomeric plasticity. Human Molecular 786 787 Genetics 9, 2879-2884. 10.1093/hmg/9.19.2879.
- 41. Salsi, V., Magdinier, F., and Tupler, R. (2020). Does DNA methylation matter in FSHD? 788 789 Genes 11. 10.3390/genes11030258.
- 790 42. Wang, T., Antonacci-Fulton, L., Howe, K., Lawson, H.A., Lucas, J.K., Phillippy, A.M., Popejoy, 791 A.B., Asri, M., Carson, C., Chaisson, M.J.P., et al. (2022). The Human Pangenome Project: a 792 global resource to map genomic diversity. Nature 604, 437–446. 10.1038/s41586-022-793 04601-8.
- 794 43. Bettio, C., Salsi, V., Orsini, M., Calanchi, E., Magnotta, L., Gagliardelli, L., Kinoshita, J., 795 Bergamaschi, S., and Tupler, R. (2021). The Italian National Registry for FSHD: an 796 enhanced data integration and an analytics framework towards Smart Health Care and 797 Precision Medicine for a rare disease. Orphanet Journal of Rare Diseases 16, 1–21. 798 10.1186/s13023-021-02100-z.
- 799 44. Li, L.C., and Dahiya, R. (2002). MethPrimer: Designing primers for methylation PCRs. 800 Bioinformatics 18, 1427–1431. 10.1093/bioinformatics/18.11.1427.
- 801 45. Altschup, S.F., Gish, W., Pennsylvania, T., and Park, U. (1990). Basic Local Alignment 802 Search Tool 2Department of Computer Science. 403–410.
- 803 46. Lassmann, T. (2020). Kalign 3: Multiple sequence alignment of large datasets. 804 Bioinformatics 36, 1928–1929. 10.1093/bioinformatics/btz795.
- 805 47. Castresana, J. (2000). Selection of conserved blocks from multiple alignments for their use 806 in phylogenetic analysis. Molecular Biology and Evolution 17, 540–552. 807 10.1093/oxfordjournals.molbev.a026334.
- 808 48. Rice, P., Longden, L., and Bleasby, A. (2000). EMBOSS: The European Molecular Biology 809 Open Software Suite. Trends in Genetics 16, 276–277. 10.1016/S0168-9525(00)02024-2.
- 810 49. Tajima, F., and Nei, M. (1984). Estimation of evolutionary distance between nucleotide 811 sequences. Molecular Biology and Evolution 1, 269–285.

- 812 50. R Core Team (2020). R: A language and environment for statistical computing. R 813 Foundation for Statistical Computing, Vienna, Austria. https://www.r-project.org/.
- 51. Andrews, S. (2010). FastOC: A Quality Control Tool for High Throughput Sequence Data. 814 815 http://www.bioinformatics.babraham.ac.uk/projects/fastqc/.
- 816 52. FastQC (2015). https://qubeshub.org/resources/fastqc.
- 817 53. Ewels, P., Lundin, S., and Max, K. (2016). Data and text mining MultiQC : summarize 818 analysis results for multiple tools and samples in a single report. 32, 3047–3048. 819 10.1093/bioinformatics/btw354.
- 820 54. Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie 2. 821 Nature Methods 9, 357-359. 10.1038/nmeth.1923.
- 822 55. Quinlan, A.R., and Hall, I.M. (2010). BEDTools : a flexible suite of utilities for comparing 823 genomic features. 26, 841–842. 10.1093/bioinformatics/btg033.
- 824 56. Krueger, F., and Andrews, S.R. (2011). Bismark: A flexible aligner and methylation caller 825 for Bisulfite-Seq applications. Bioinformatics 27, 1571–1572. 826 10.1093/bioinformatics/btr167.
- 827 57. Chang, X.; Wang, K. (2008). wANNOVAR: annotating genetic variants for personal 828 genomes via the web. Journal of Human Genetics 6, 2166–2171. 10.1136/jmedgenet-829 2012-100918.wANNOVAR.
- 830 58. Chen, K., Hu, J., Moore, D.L., Liu, R., Kessans, S.A., Breslin, K., Lucet, I.S., Keniry, A., Leong, 831 H.S., Parish, C.L., et al. (2015). Genome-wide binding and mechanistic analyses of Smchd1-832 mediated epigenetic regulation. Proceedings of the National Academy of Sciences of the 833 United States of America *112*, E3535–E3544. 10.1073/pnas.1504232112.
- 59. Kopanos, C., Tsiolkas, V., Kouris, A., Chapple, C.E., Albarca Aguilera, M., Meyer, R., and 834 835 Massouras, A. (2019). VarSome: the human genomic variant search engine. Bioinformatics 836 35, 1978-1980. 10.1093/bioinformatics/btv897.
- 837 60. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, R.H., and Committee., A.L.Q.A. (2015). Standards and guidelines 838 839 for the interpretation of sequence variants: a joint consensus recommendation of the 840 American College of Medical Genetics and Genomics and the Association for Molecular 841 Pathology. Genet Med 17, 405-424. 10.1038/gim.2015.30.
- 842 61. Scionti, I., Greco, F., Ricci, G., Govi, M., Arashiro, P., Vercelli, L., Berardinelli, A., Angelini, C., 843 Antonini, G., Cao, M., et al. (2012). Large-scale population analysis challenges the current 844 criteria for the molecular diagnosis of fascioscapulohumeral muscular dystrophy. 845 American Journal of Human Genetics 90, 628–635. 10.1016/j.ajhg.2012.02.019.
- 62. Delourme, M., Charlene, C., Gerard, L., Ganne, B., Perrin, P., Vovan, C., Bertaux, K., Nguyen, 846 847 K., and Magdinier, F. (2023). Complex 4q35 and 10q26 Rearrangements. 10.1212/NXG.000000000200076. 848
- 849 63. Cacurri, S., Piazzo, N., Deidda, G., Vigneti, E., Galluzzi, G., Colantoni, L., Merico, B., Ricci, E., 850 and Felicetti, L. (1998). Sequence homology between 4qter and 10qter loci facilitates the

medRxiv preprint doi: https://doi.org/10.1101/2023.06.13.23291337; this version posted August 2, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

- instability of subtelomeric KpnI repeat units implicated in facioscapulohumeral muscular 851 852 dystrophy. American Journal of Human Genetics 63, 181–190. 10.1086/301906.
- 64. Lemmers, R.J.L.F., van der Vliet, P.J., van der Gaag, K.J., Zuniga, S., Frants, R.R., de Knijff, P., 853 and van der Maarel, S.M. (2010). Worldwide Population Analysis of the 4g and 10g 854 Subtelomeres Identifies Only Four Discrete Interchromosomal Sequence Transfers in 855 856 Human Evolution. American Journal of Human Genetics 86, 364–377. 857 10.1016/j.ajhg.2010.01.035.
- 858 65. de Greef, J.C., Lemmers, R.J.L.F., van Engelen, B.G.M., Sacconi, S., Venance, S.L., Frants, R.R., 859 Tawil, R., and van der Maarel, S.M. (2009). Common epigenetic changes of D4Z4 in 860 contraction-dependent and contraction-independent FSHD. Human Mutation 30, 1449-861 1459. 10.1002/humu.21091.
- 66. Hewitt, J.E., Lyle, R., Clark, L.N., Valleley, E.M., Wright, T.J., Wijmenga, C., Van Deutekom, J.C. 862 863 t., Francis, F., Sharpe, P.T., Hofker, M., et al. (1994). Analysis of the tandem repeat locus 864 D4Z4 associated with facioscapulohumeral muscular dystropothhy. Human Molecular Genetics 3, 1287–1295. 10.1093/hmg/3.8.1287. 865
- 67. Pini, S., Napoli, F.M., Tagliafico, E., La Marca, A., Bertucci, E., Salsi, V., and Tupler, R. (2023). 866 867 De novo variants and recombination at 4q35: Hints for preimplantation genetic testing in facioscapulohumeral muscular dystrophy. Clinical Genetics 103, 242-246. 868 869 10.1111/cge.14250.
- 68. Gaillard, M.C., Roche, S., Dion, C., Tasmadjian, A., Bouget, G., Salort-Campana, E., Vovan, C., 870 Chaix, C., Broucqsault, N., Morere, J., et al. (2014). Differential DNA methylation of the 871 872 D4Z4 repeat in patients with FSHD and asymptomatic carriers. Neurology 83, 733–742. 10.1212/WNL.0000000000000708. 873
- 874 69. Lemmers, R.J.L.F., Goeman, J.J., Van der Vliet, P.J., Van Nieuwenhuizen, M.P., Balog, J., Vos-875 Versteeg, M., Camano, P., Ramos Arroyo, M.A., Jerico, I., Rogers, M.T., et al. (2015). Inter-876 individual differences in CpG methylation at D4Z4 correlate with clinical variability in 877 FSHD1 and FSHD2. Human Molecular Genetics 24, 659–669. 10.1093/hmg/ddu486.
- 878 70. Jones, T.I., King, O.D., Himeda, C.L., Homma, S., Chen, J.C.J., Beermann, M. Lou, Yan, C., 879 Emerson, C.P., Miller, J.B., Wagner, K.R., et al. (2015). Individual epigenetic status of the 880 pathogenic D4Z4 macrosatellite correlates with disease in facioscapulohumeral muscular 881 dystrophy. Clinical Epigenetics 7, 1–22. 10.1186/s13148-015-0072-6.
- 882 71. Calandra, P., Cascino, I., Lemmers, R.I.L.F., Galluzzi, G., Teveroni, E., Monforte, M., Tasca, G., Ricci, E., Moretti, F., Van Der Maarel, S.M., et al. (2016). Allele-specific DNA 883 884 hypomethylation characterises FSHD1 and FSHD2. Journal of Medical Genetics 53, 348-885 355. 10.1136/jmedgenet-2015-103436.
- 72. Dion, C., Roche, S., Laberthonnière, C., Broucqsault, N., Mariot, V., Xue, S., Gurzau, A.D., 886 887 Nowak, A., Gordon, C.T., Gaillard, M.C., et al. (2019). SMCHD1 is involved in de novo 888 methylation of the DUX4-encoding D4Z4 macrosatellite. Nucleic Acids Research 47, 2822-889 2839.10.1093/nar/gkz005.
- 890 73. Hiramuki, Y., Kure, Y., Saito, Y., Ogawa, M., Ishikawa, K., Yoshimura, M.M., Oya, Y., 891 Takahashi, Y., Kim, D.S., Arai, N., et al. (2022). Simultaneous measurement of the size and methylation of chromosome 4qA - D4Z4 repeats in facioscapulohumeral muscular 892

- 893 dystrophy by long - read sequencing. Journal of Translational Medicine, 1–12. 894 10.1186/s12967-022-03743-7.
- 895 74. Erdmann, H., Scharf, F., Gehling, S., Benet-Pagès, A., Jakubiczka, S., Becker, K., Seipelt, M., Kleefeld, F., Knop, K.C., Prott, E.-C., et al. (2023). Methylation of the 4q35 D4Z4 repeat 896 defines disease status in facioscapulohumeral muscular dystrophy. Brain 146, 1388–1402. 897 898 10.1093/brain/awac336.
- 899 75. Butterfield, R.I., Dunn, D.M., Duvall, B., Moldt, S., and Weiss, R.B. (2023). Deciphering D4Z4 900 CpG methylation gradients in fascioscapulohumeral muscular dystrophy using nanopore 901 sequencing. bioRxiv : the preprint server for biology. 10.1101/2023.02.17.528868.
- 902 76. Lemmers, R.J.L.F., Wohlgemuth, M., Van Der Gaag, K.J., Van Der Vliet, P.J., Van Teijlingen, 903 C.M.M., De Knijff, P., Padberg, G.W., Frants, R.R., and Van Der Maarel, S.M. (2007). Specific 904 sequence variations within the 4q35 region are associated with facioscapulohumeral muscular dystrophy. American Journal of Human Genetics 81, 884–894. 10.1086/521986. 905
- 906 77. Tawil, R., Kissel, J.T., Heatwole, C., Pandya, S., Gronseth, G., and Benatar, M. (2015). 907 Evidence-based guideline summary: Evaluation, diagnosis, and management of 908 facioscapulohumeral muscular dystrophy. Neurology 85, 357–364. 909 10.1212/WNL.000000000001783.
- 910

Figure titles and legends 911

912

Figure 1. Scheme of the proposed models for FSHD1 and FSHD2 pathogenesis 913

914 Tandemly arrayed D4Z4 repeats (triangles) and the 4g35 haplotype elements are 915 represented along with the molecular signatures proposed for FSHD1 and FSHD2 916 pathogenesis.

917

918 Figure 2. Stratification and variability of D4Z4-I elements

- 919 (A) D4Z4-I elements in hg38 and T2T. Cumulative size per chromosome of D4Z4-I elements.
- 920 Only chromosomes for which at least 1 Kb of D4Z4-I sequence was identified, in any of the
- 921 2 assemblies, are reported. Size (in Kb) is shown on the Y axis. Different colors are used
- 922 for T2T and hg38 and to mark complete D4Z4-I (see legend). (B) Cumulative size (in Kb) of
- 923 D4Z4-I elements in the hg38, T2T and PGR haplotype level assemblies. Left: cumulative
- 924 size of D4Z4-I elements. Right: cumulative size of full D4Z4-I elements. Data is displayed in

925 the form of a barplot. Values are on the Y axis, labels on the X axis. For the human 926 pangenome haplotype level assemblies, 3 distinct bars are used to indicate the minimum, 927 maximum and average values. Color codes according to the legend. (C) Dendrogram of 928 complete D4Z4-I elements. Red rectangles and color codes are used to delineate the 5 main 929 groups of D4Z4-I elements, as identified by sequence similarity-based clustering. (D) Total 930 estimated number of complete D4Z4 elements per sequence similarity group. Distributions 931 of values are displayed in the form of a boxplot, with groups indicated on the X axis and 932 copy numbers on the Y axis. The top-right panel provides zoom on groups chr 14, chr 15-933 21, chr 22-1 and chr 22-2.

934

935 Figure 3. Characterization of D4Z4 alleles

936 (A) Heatmap of ter-DUX4. Scaled identity levels are displayed by the green color gradient 937 on the right. The dendrogram on the left shows clustering of ter-DUX4 based on sequence 938 identity. Colored vertical bars are used to indicate: presence/absence of pLam; classification 939 as qA or qB; sequence similarity cluster (see top). Color codes are explained directly under 940 each bar. (B) Numerosity of sequence similarity clusters. The barplot shows (y-axis) the 941 total number of ter-DUX4 in each cluster (x-axis). (C) Boxplot of substitution rates. 942 Substitution rates (substitutions by 100 bp) by cluster. Distribution of values are shown as 943 a boxplot. Clusters are on the y-axis, values on the x-axis. (D) Distance of qA and qB 944 elements from ter-DUX4. Data are represented in the form of a histogram. Distances (in Kb) 945 are indicated on the x-axis. qA and qB elements are marked with different colors (see 946 legend). (E-G) Annotation of terminal D4Z4 repeats. Two barplots are displayed for the 3 947 (out of 4) clusters to which 5 or more sequences have been assigned. Each barplot reports, 948 for qA and qB alleles respectively: the total count (tot); the number pLam-like elements 949 (pLam); the number pLam-like elements with a valid PAS (plamPolyA); the total number of 950 haplotypes with 8 or less D4Z4 repeats. Values are indicated on the y-axis, labels on the x-

951 axis. Distinct sequence similarity clusters are indicated by a corresponding label directly 952 under each plot. (G-H) Total number of complete D4Z4-I elements in H) qA and qB 953 haplotypes; I) haplotypes with (pLam+) and without (pLam-). Distribution of values are 954 displayed in the form of a boxplot, with values on the X-axis and groups on the Y axis. Color 955 codes are consistent throughout Figure 2.

956

957 Figure 4. CpG Methylation profiles of cohort subjects inferred on T2T

958 A total of 82 CpGs for which complete data are available for all the study subjects are shown. 959 (A) Heatmap of % CpG methylation: each row represents the CpG methylation pattern of a 960 single individual. Columns represent the methylation pattern of each analyzed CpG. The dendrogram shows the clustering of the subjects based on the observed methylation 961 962 profiles. Colored vertical bars are used to display CCEF clinical category status, and the 963 presence/absence of deleterious genomic variants in SMCHD1. Color codes are illustrated 964 directly under each bar. The colored bar at the top demarcates each of the 4 distinct 95% 965 sequence identity genomic region clusters with complete data for all the subjects. (B) 966 Boxplots of methylation levels distributions by subject. The color-scale used for the heatmap 967 and the boxplot is shown at the bottom. (C) Violin-plot of average methylation levels, 968 restricted to CpGs in regions GS1 and GS6, in subjects with/without deleterious genetic 969 variants in SMCHD1.

970

971 Figure 5. Methylation profiles of cohort subjects inferred on hg38

A total of 32 distinct CpGs, for which complete data are available for all the study subjects, are displayed. (A) Heatmap of % CpG methylation: individuals are reported on the rows and CpGs on the columns. The dendrogram shows a clustering of the subjects based on the observed methylation profiles. Colored vertical bars are used to display CCEF grades, and the presence/absence of deleterious genomic variants in *SMCHD1*. Color codes are

977 illustrated directly under each bar. The colored bar at the top demarcates each of the 4 978 distinct 95% sequence identity genomic regions clusters with complete data for all the 979 subjects. (B) Boxplots of methylation levels distributions by subject. The color-scale used 980 for the heatmap and the boxplot is shown at the bottom. (C) Violin-plot of average 981 methylation levels in subjects with/without deleterious genetic variants in *SMCHD1*. Only 982 CpGs in primer-targeted regions are considered.

983

984 Figure 6. Genotype-phenotype correlation

985 (A) Venn diagrams reporting the number of subjects presenting different combinations of 4q/10q-specific D4Z4 methylation level, SMCHD1 mutational status and FSHD clinical 986 987 category. (B) ACMG classification, median 4g/10g-specific D4Z4 methylation of variant 988 carriers, variant type and location are reported for each SMCHD1 variant. When the variant 989 is carried by more than one subject, median D4Z4 methylation status of all the subjects is 990 reported. (C) Distribution of 4q/10q-specific D4Z4 methylation, SMCHD1 mutational status 991 and FSHD clinical category in the 8 trios/parent-child couples included in the study. 992 Circles/squares are colored according to the median 4g/10g-specific D4Z4 methylation 993 level; the color is fading as it represents the variability of CpG methylation pattern in each 994 individual. WT= subject carrying no SMCHD1 variants, VAR= subject carrying a damaging 995 SMCHD1 variants.

996

997

- 998
- 999
- 1000
- 1001

1002 Table titles and legends

1003

1004 Table 1. Titration analysis for the identification of the optimal sequence similarity

1005 threshold

			uniquely mapped	# testable
Identity-level (%)	# regions	size (Kb)	BSC reads (%)	CpGs
99	145	67,41	5,43%	237
98	103	59,13	12,13%	411
97	87	54,01	26,74%	873
96	73	46,14	32,47%	997
95	60	40,03	49,17%	1176
94	56	38,71	51,01%	1083
93	53	37,55	53,43%	891
92	46	36,49	58,47%	766
91	45	33,02	72,71%	637
90	42	32,75	75,41%	451

Identity-level (%): sequence identity threshold. #regions: number of distinct regions defined
by the threshold. size (Kb): total size of the regions in Kb. uniquely mapped BSC reads (%):
percentage of uniquely mapping BSC reads. # testable CpGs: total number of distinct CpGs
for which more than 10 reads were available for more than 25 subjects. Italic characters
indicate the selected sequence similarity threshold.

- 1011
- 1012
- 1013
- 1014
- 1015
- 1016

Table 2. Characterization of complete D4Z4 elements clusters

Cluster	Chromosome	% sequences	Median	Average	Substitution
			number of	substitution	rates estimates
			complete	rate per 100	at haplotype
			repeats (per	bp	level
			haplotype)		
1	Chr 10	87%	19	0.13	0.015-0.21
2	Chr 4		22	0.245	0.164-0.4312
3	Chr 14	2.3%	0.5	1.73	NA
4	Chr 15, Chr 21	3.1%	1	1.81	NA
5	Chr 22-1	1.5%+6.1%	0	0.798	NA
6	Chr 22-2		2	1.24	NA

Table 3 [.]	comparison between PGR analysis results and previous knowledge		
Haploty	σ	PGR analysis	Previous knowledge
4qA 4qA	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	 6 to 89 RU alleles; The majority of alleles classified as qA are associated with a pLam both on 4q and 10q; AUUAAA PAS at 4q; AUUAAA PAS at 4q; AUUAAA PAS at 4q; AUUAAA PAS at 4q; AUUAAA PAS at and 10q; AUUAAA PAS at 4q; AUUAAA PAS at and 10q; AUUAAA PAS at and 10q; 	- 6 to ~90 RU alleles ⁴⁰ ; - qA alleles are associated with a pLam both on 4q and 10q ¹⁸ ; - AUUAAA PAS at 4q ⁶⁴ ; - 3% healthy population carry a DRA and 1.3% a DRA with 4qA-PAS haplotype ³⁹ .
4qB	Centre for Kind Kind Kind Dud Kind Dud Kind Centre for Kind Bud Ki	- qB alleles do not carry a pLam sequence; - qB sequence is more proximal than qA (2.5 Kb and 7.3 Kb and 7.3 Kb and 7.3 Kb respectively); - No differences in D424 repeat numbers between 4qA and 4qB alleles.	- qB alleles do not carry a pLam sequence ¹⁸ ; - qB sequence is more proximal than qA ¹⁹ ; - Observed equal frequency of 4qA and 4qB alleles ¹⁹ .
10qA 10qB	Cen- Kan	- AUCAAA PAS at 10q; - One 10qB allele was identified.	 - AUCAAA PAS at 100⁶⁴; - 10q is associated predominantly to qA haplotype¹⁹; - sporadic cases of 10qB alleles⁶².

Table 4: GS containing CpGs covered by at least 10 BSC reads in at least 50% of 1032

1033 samples and no missing data across all samples

Assembly	Group	Chromosome	N° CpGs
T2T	GS1	Chr 4, Chr 10	28
	GS2		32
	GS5	Chr 13, Chr 15	16
	GS6		5
hg38	GS3	Chr 4, Chr 10	26















----4

----4 -----

----4

-------4

---4

----4

----4

----4

+----

+----

+----

+----



GS3

A

